Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Personalized immunotherapy (AGS-003) when combined with sunitinib for the treatment of metastatic renal cell carcinoma
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 8, Pages 1241-1248
Publisher
Informa Healthcare
Online
2015-06-30
DOI
10.1517/14712598.2015.1063610
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of Immunotherapy for Renal Cell Cancer in 2011
- (2017) Saby George et al. Journal of the National Comprehensive Cancer Network
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- (2015) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer
- (2015) Alexandra Kirner et al. Human Vaccines & Immunotherapeutics
- First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
- (2014) J J Ko et al. BRITISH JOURNAL OF CANCER
- Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma
- (2014) David Cella et al. CANCER
- IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy
- (2014) Steffen Rausch et al. Future Oncology
- Priming of a Novel Subset of CD28+ Rapidly Expanding High-Avidity Effector Memory CTL by Post Maturation Electroporation-CD40L Dendritic Cells Is IL-12 Dependent
- (2014) M. A. DeBenedette et al. JOURNAL OF IMMUNOLOGY
- Renal cell carcinoma
- (2014) E. Jonasch et al. BMJ-British Medical Journal
- Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy
- (2013) Valerie R. Yanofsky et al. Clinical & Developmental Immunology
- Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies
- (2013) Pawel Kalinski et al. Expert Review of Vaccines
- Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
- (2013) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
- (2012) Steffen Walter et al. OncoImmunology
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
- (2011) Benedetto Farsaci et al. INTERNATIONAL JOURNAL OF CANCER
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
- (2011) T. E. Hutson ONCOLOGIST
- Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities
- (2011) C. Kollmannsberger et al. ONCOLOGIST
- Immunotherapy of metastatic renal cell carcinoma
- (2010) David F. McDermott CANCER
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
- (2010) Stéphane Oudard et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination
- (2010) Anamika Bose et al. INTERNATIONAL JOURNAL OF CANCER
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Potency of Mature CD40L RNA Electroporated Dendritic Cells Correlates With IL-12 Secretion by Tracking Multifunctional CD8+/CD28+ Cytotoxic T-cell Responses In Vitro
- (2010) Mark A. DeBenedette et al. JOURNAL OF IMMUNOTHERAPY
- Treatment of metastatic renal cell carcinoma
- (2010) Maxine Sun et al. Nature Reviews Urology
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma
- (2009) Premal H. Patel et al. Clinical Genitourinary Cancer
- Multipeptide vaccination in cancer patients
- (2009) Lorenzo Pilla et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Darren R. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy
- (2009) Michael B. Atkins MEDICAL ONCOLOGY
- Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
- (2008) M. M. Hipp et al. BLOOD
- Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
- (2008) J. H. Finke et al. CLINICAL CANCER RESEARCH
- Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response
- (2008) David M. Calderhead et al. JOURNAL OF IMMUNOTHERAPY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now